Skip to main content
Premium Trial:

Request an Annual Quote

Startup Norton Signs Sales Deals Covering Europe, mid-Atlantic States

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup firm Norton Scientific separately announced an agreement to expand its sales presence in Europe and a deal for the sale of its products in the mid-Atlantic region.

Earlier this month, the company based in Thorold, Canada, announced a mutual distribution agreement under which AstraNet Systems, in Cambridge, UK, would sell Norton's recently launched protein aggregation monitoring, or PAM, hand-held system for the analysis of how proteins aggregate in solutions.

In return, Norton will promote the AstraGene UV low volume spectrophotometer for nucleic acid and proteins through its North American sales network.

In a separate announcement, Norton said this week it has signed up Columbia, Md.-based Advanced Scientific Technologies to sell the PAM and AstraGene products in the District of Columbia, Maryland, Delaware, Virginia, south and central Pennsylvania, and south New Jersey.

Financial and other terms of the two deals were not disclosed.

Norton was founded in 2010 and designs and develops products for proteomics research. The company said on its website that it also is developing its IP base in mechatronic systems, microfluidics, guided wave optical detection, multivariate analysis software for real-time process control, and macromolecular and nanoparticle separations.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.